• Vinayak Kohli
    Vinayak Kohli
    • over 8 years ago
    • Practical Guidance Journal
    • pa

    Strategies and Opportunities in an America Invents Act World – Choices of Venue

    By: Ethan Horwitz , Carlton Fields. TODAY, BOTH PATENT OWNERS AND ACCUSED INFRINGERS have multiple choices of venues in which to litigate the validity of a patent. There is the historic option of a patent infringement case in the federal courts. Increasingly...
  • Vinayak Kohli
    Vinayak Kohli
    • over 7 years ago
    • Practical Guidance Journal
    • pa

    Preparing for Random Trademark Registration Audits

    By: Janet Marvel Pattishall, Mcauliffe, Newbury, Hilliard & Geraldson LLP The U.S. Patent and Trademark Office (USPTO) is commencing random audits of trademark registrations in which Declarations of Use have been filed to verify that the registered...
  • Vinayak Kohli
    Vinayak Kohli
    • over 8 years ago
    • Practical Guidance Journal
    • pa

    Reverse Yankee Bonds and the New EU Market Abuse Regime

    By: Matthew Merkle , Kirkland & Ellis International LLP. ON JULY 3, 2016, THE EUROPEAN UNION (EU) WILL EXTEND its new market abuse regime (MAD II) 2 to the previously unregulated Global Exchange Market of the Irish Stock Exchange (GEM) and the EuroMTF...
  • Vinayak Kohli
    Vinayak Kohli
    • over 7 years ago
    • Practical Guidance Journal
    • pa

    Biometric Information Protection: The Stage is Set for Expansion of Claims

    By: Torsten M. Kracht, Michael J. Mueller, Lisa J. Sotto, and Daniella Sterns Hunton & Williams LLP Litigation alleging the improper collection and storage of biometric data is being driven by the Illinois Biometric Information Protection Act (BIPA...
  • Vinayak Kohli
    Vinayak Kohli
    • over 6 years ago
    • Practical Guidance Journal
    • pa

    Biosimilars and The Biologics Price Competition and Innovation Act (BPCIA)

    By: Michael Furrow , DLA Piper, and Whitney Meier , Venable LLP The Biologics Price Competition and Innovation Act (BPCIA) provides an abbreviated pathway for companies to bring biologic drugs to market that are biosimilar to previously approved branded...
<>